Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Factors contributing to retroviral integration have been intractable because past studies have not precisely located genomic sites of proviruses in sufficient numbers for significant analysis. In this study, 903 murine leukemia virus (MLV) and 379 human immunodeficiency virus–1 (HIV-1) integrations in the human genome were mapped. The data showed that MLV preferred integration near the start of transcriptional units (either upstream or downstream) whereas HIV-1 preferred integration anywhere in the transcriptional unit but not upstream of the transcriptional start. Defining different integration site preferences for retroviruses will have important ramifications for gene therapy and may aid in our understanding of the factors directing the integration process.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The well-understood integration preferences of HIV-1 for active transcription units72 and MLV for promoter/enhancer regions73–75 are in large part dictated via specific interactions of the respective IN proteins with chromatin-bound host factors.”
From Structure and function of retroviral integrase (2022) · cites this paper as [73]
In the citing paper
“Multiple studies now indicate that gammaretroviral vectors such as the vectors used in the two SCID-X1 trials preferentially integrate into the 5′ end of genes, near the transcription start sites[47].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [47]
In the citing paper
“Finally, the preferred sequences of the genome for integration are different from the γ-RVV, with LVV preferentially integrating in genes and introns away for transcriptional start sites preferred by γ-RVV.20”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [20]
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.-P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,058
CpG islands as gene markers in the human genome
Larsen, F., Gundersen, G., Lopez, R., & Prydz, H. (1992) · Genomics · doi:10.1016/0888-7543(92)90024-m · Cited by 922
Pryciak, P. M., & Varmus, H. E. (1992) · Cell · doi:10.1016/0092-8674(92)90289-o · Cited by 273
Introducing RefSeq and LocusLink: curated human genome resources at the NCBI
Pruitt, K. D., Katz, K. S., Sicotte, H., & Maglott, D. R. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01882-x · Cited by 241
Check, E. (2002) · Nature · doi:10.1038/420116a · Cited by 238
Pruss, D., Bushman, F. D., & Wolffe, A. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5913 · Cited by 236
Transcriptionally active genome regions are preferred targets for retrovirus integration
Scherdin, U., Rhodes, K., & Breindl, M. (1990) · Journal of Virology · doi:10.1128/jvi.64.2.907-912.1990 · Cited by 210
Research works printed but not linked: 2
- National Center for Biotechnology Information Reference Sequence Project (RefSeq) www.ncbi.nlm.nih.gov/RefSeq/.
- The database is available online at www.ncbi.nlm.nih.gov/geo/.
Cited by
Items 401–500 of 1,000
Transgenes as screening tools to probe and manipulate the zebrafish genome
Amsterdam, A., & Becker, T. S. (2005) · Developmental Dynamics · doi:10.1002/dvdy.20541 · Cited by 58
“…insertion preference of the retrovirus, as has been suggested in mice (Scherdin et al., 1990; Mooslehner et al., 1990), human tissue culture cells (Wu et al., 2003), and the cloning of a large number of unselected viral insertions in zebrafish (G. Golling and T. Thacker, personal communication,…”
BackgroundRecent developments in transposon-mediated gene therapy
Matteo, M. D., Belay, E., Chuah, M., & VandenDriessche, T. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.684875 · Cited by 63
“Consequently, the integration pattern of the SB transposon system seems safer compared to when integrating viral vectors are used [94,96-100].”
MethodAlmarza, D., Bussadori, G., Navarro, M., Mavilio, F., Larcher, F., & Murillas, R. (2011) · Gene Therapy · doi:10.1038/gt.2011.12 · Cited by 56
“Lentiviral insertion analysis Proviral integration sites were cloned by LM-PCR as described elsewhere”
MethodPolyclonal fluctuation of lentiviral vector–transduced and expanded murine hematopoietic stem cells
Maetzig, T., Brugman, M. H., Bartels, S., Heinz, N., Kustikova, O. S., Modlich, U., Li, Z., Galla, M., Schiedlmeier, B., Schambach, A., et al. (2011) · Blood · doi:10.1182/blood-2010-08-303222 · Cited by 55
Uchida, N., Washington, K. N., Hayakawa, J., Hsieh, M. M., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Donahue, R. E., & Tisdale, J. F. (2009) · Journal of Virology · doi:10.1128/jvi.00357-09 · Cited by 56
“Subsequent adverse events associated with insertional mutagenesis have led to a reassessment of the risks associated with retroviral vector integration (6, 12), and a bias of murine leukemia virus (MLV)based gammaretroviral vectors to integrate near transcription start sites (18, 24, 40) has prompted exploration of al…”
BackgroundSleeping Beauty transposition: from biology to applications
Narayanavari, S. A., Chilkunda, S. S., Ivics, Z., & Izsvák, Z. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2016.1237935 · Cited by 62
“Curiously, the piggyBac transposon displays an integration profile highly similar to that of the MLV retrovirus (de Jong et al., 2014; Wu et al., 2003), and both MLV integrase and the piggyBac transposase interact physically with BET proteins for guided integrations to specific chromatin environments (de Rijck et al.”
BackgroundMethodOhlfest, J. R., Lobitz, P. D., Perkinson, S. G., & Largaespada, D. A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.005 · Cited by 56
Mobilization and Mechanism of Transcription of Integrated Self-Inactivating Lentiviral Vectors
Hanawa, H., Persons, D. A., & Nienhuis, A. W. (2005) · Journal of Virology · doi:10.1128/jvi.79.13.8410-8421.2005 · Cited by 54
“Interruption of a critical gene by vector integration will also remain as a finite risk, since both oncoretroviral and lentiviral vectors preferentially integrate into transcriptionally active genes (43, 50).”
BackgroundDeciphering the Code for Retroviral Integration Target Site Selection
Santoni, F. A., Hartley, O., & Luban, J. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001008 · Cited by 54
“MLV [31] proviruses were cloned from HeLa cells, XMRV proviruses from DU145, and PERV proviruses from HEK 293.”
BackgroundMethodInfluentialYoshimitsu, M., Higuchi, K., Ramsubir, S., Nonaka, T., Rasaiah, V. I., Siatskas, C., Liang, S.-B., Murray, G. J., Brady, R. O., & Medin, J. A. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302839 · Cited by 60
Lee, H. B., Park, J., Forget, B. G., & Gaines, P. C. W. (2009) · Regenerative Medicine · doi:10.2217/rme.09.46 · Cited by 63
Salas, M. J., Vannier, J., & Williams, M. (2007) · Journal of Paleontology · doi:10.1666/05-134.1 · Cited by 55
Insertional mutagenesis and clonal dominance: biological and statistical considerations
Fehse, B., & Roeder, I. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303052 · Cited by 62
MacNeil, A., Sankalé, J.-L., Meloni, S. T., Sarr, A. D., Mboup, S., & Kanki, P. (2006) · Journal of Virology · doi:10.1128/jvi.00604-06 · Cited by 51
“MLV has been shown to have a strong tendency towards integration near CpG islands and near sites of transcriptional initiation (27, 41).”
BackgroundMethodResultInfluentialDavis, R. P., Nemes, C., Varga, E., Freund, C. M. A. H., Kosmidis, G., Gkatzis, K., de Jong, D., Szuhai, K., Dinnyés, A., & Mummery, C. L. (2013) · Differentiation · doi:10.1016/j.diff.2013.06.002 · Cited by 60
Amberger, M., & Ivics, Z. (2020) · BioEssays · doi:10.1002/bies.202000136 · Cited by 54
Ariumi, Y., Serhan, F., Turelli, P., Telenti, A., & Trono, D. (2006) · Retrovirology · doi:10.1186/1742-4690-3-47 · Cited by 61
“Retroviral integration favors active genes, MLV concentrating in and around promoters while HIV tends to land in the transcribed region of genes [33-35].”
BackgroundInagaki, K., Lewis, S. M., Wu, X., Ma, C., Munroe, D. J., Fuess, S., Storm, T. A., Kay, M. A., & Nakai, H. (2007) · Journal of Virology · doi:10.1128/jvi.00963-07 · Cited by 54
“Murine leukemia virus preferentially integrates near transcription start sites (59), while human immunodeficiency virus favors transcribed regions for integration (49).”
BackgroundMethodSelf-citationHackett, P. B., Aronovich, E. L., Hunter, D. W., Urness, M., Bell, J. B., Kass, S. J., Cooper, L. J. N., & McIvor, S. R. (2011) · Current Gene Therapy · doi:10.2174/156652311797415827 · Cited by 53
Gene therapy for severe combined immune deficiency
Qasim, W., Gaspar, H. B., & Thrasher, A. J. (2004) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399404007884 · Cited by 53
Two independent retrotransposon insertions at the same site within the coding region of BTK
Conley, M. E., Partain, J. D., Norland, S. M., Shurtleff, S. A., & Kazazian, H. H. (2005) · Human Mutation · doi:10.1002/humu.9321 · Cited by 50
“By contrast, Wu et al. did not demonstrate any hot spots when HeLa cells were infected with MLV or HIV-1 (Wu et al., 2003).”
BackgroundResultTransposons as tools for enhancer trap screens in vertebrates
Korzh, V. P. (2007) · Genome biology · doi:10.1186/gb-2007-8-s1-s8 · Cited by 53
“It has been shown that MLV prefers to insert into the promoters of active genes [24], which in principle makes it a useful tool for generating regulatory mutants.”
BackgroundTargeted plasmid integration into the human genome by an engineered zinc-finger recombinase
Gersbach, C. A., Gaj, T., Gordley, R. M., Mercer, A. C., & Barbas, C. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr421 · Cited by 58
“These vectors integrate semi-randomly into the genome with a preference for promoters or intragenic regions of actively transcribed genes (2,3).”
Fragile sites are preferential targets for integrations of MLV vectors in gene therapy
Bester, A. C., Schwartz, M., Schmidt, M., Garrigue, A., Hacein‐Bey‐Abina, S., Cavazzana, M., Ben-Porat, N., Kalle, C. V., Fischer, A., & Kerem, B. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302752 · Cited by 52
Host Factors That Affect Ty3 Retrotransposition in Saccharomyces cerevisiae
Aye, M., Irwin, B., Beliakova‐Bethell, N., Chen, E., Garrus, J. E., & Sandmeyer, S. B. (2004) · Genetics · doi:10.1534/genetics.104.028126 · Cited by 57
“In the course of the transposition Ty3 RNA viruses into transcribed regions (Schroder et al. 2002; was produced from which the synthetic intron in the HIS3AI Wu et al. 2003).”
BackgroundStructural basis for spumavirus GAG tethering to chromatin
Lesbats, P., Serrao, E., Maskell, D. P., Pye, V. E., O’Reilly, N., Lindemann, D., Engelman, A. N., & Cherepanov, P. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621159114 · Cited by 51
LeBlanc, J., Weil, J., & Beemon, K. (2013) · WIREs RNA · doi:10.1002/wrna.1179 · Cited by 47
BET-independent MLV-based Vectors Target Away From Promoters and Regulatory Elements
El Ashkar, S., De Rijck, J., Demeulemeester, J., Vets, S., Madlala, P., Cermakova, K., Debyser, Z., & Gijsbers, R. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.33 · Cited by 47
Kim, Y.-J., Kim, Y.-S., Larochelle, A., Renaud, G., Wolfsberg, T. G., Adler, R., Donahue, R. E., Hematti, P., Hong, B.-K., Roayaei, J., et al. (2009) · Blood · doi:10.1182/blood-2008-10-185199 · Cited by 51
Retroviral Vectors for Gene Therapy
Maier, P., Kalle, C. V., & Laufs, S. (2010) · Future Microbiology · doi:10.2217/fmb.10.100 · Cited by 55
Touw, I. P., & Erkeland, S. J. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300040 · Cited by 56
Wu, Y. C., Gao, T., Wang, X., Hu, Y., Hu, X., Hu, Z., Pang, J., Li, Z., Xue, J., Feng, M., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.099 · Cited by 55
Genetic Modification of T Cells
Morgan, R. A., & Boyerinas, B. (2016) · Biomedicines · doi:10.3390/biomedicines4020009 · Cited by 55
“Genome-wide analysis studi s have demonstrated that gamma retroviruses preferentially integrate near transcription start sit s and CpG islands, and that this preferential integratio profile increases the chances of oncogenic transformation compared to a more random integration pr file [14].”
A Rapid and Quantitative Assay for Measuring Neighboring Gene Activation by Vector Proviruses
Hendrie, P. C., Huo, Y., Stolitenko, R. B., & Russell, D. W. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300398 · Cited by 52
Greene, M. R., Lockey, T., Mehta, P. K., Kim, Y.-S., Eldridge, P. W., Gray, J. T., & Sorrentino, B. P. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.150 · Cited by 47
“…vectors may be intrinsically safer than c-retroviral vectors (Montini et al., 2006) because of a different insertional profile, which less frequently targets gene regulatory regions and specific proto-oncogenes (Schröder et al., 2002; Wu et al., 2003; Hematti et al., 2004; Mitchell et al., 2004).”
BackgroundHigh, K. A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01460.x · Cited by 51
Li, Y., Rosso, M. G., Ülker, B., & Weißhaar, B. (2006) · Genomics · doi:10.1016/j.ygeno.2005.12.010 · Cited by 50
“Wu and colleagues [23] reported that the murine leukemia virus prefers integration near the transcription initiation sites in the human genome.”
BackgroundSelf-citationKikuta, H., Fredman, D., Rinkwitz, S., Lenhard, B., & Becker, T. S. (2007) · Genome biology · doi:10.1186/gb-2007-8-s1-s4 · Cited by 54
“Wu and coworkers [20] found a significant bias of MLV to insert near to transcription start sites, but no obvious hotspots for integrations.”
BackgroundSchneider, W. M., Brzezinski, J. D., Aiyer, S., Malani, N., Gyuricza, M., Bushman, F. D., & Roth, M. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221736110 · Cited by 49
“In contrast, infection by gammaretroviruses such as murine leukemia virus (MuLV) requires cell division (2), and integration is biased toward transcriptional start sites (3, 4) and CpG islands (3, 5).”
BackgroundMetanat, Y., Viktor, P., Amajd, A., Kaur, I., Hamed, A. M., Al-Abadi, N. K. A., Alwan, N. H., Chaitanya, M., Natrayan, L., Ghildiyal, P., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122683 · Cited by 50
Sfanos, K. S., Aloia, A. L., Hicks, J. L., Esopi, D., Steranka, J. P., Shao, W., Sánchez-Martínez, S., Yegnasubramanian, S., Burns, K. H., Rein, A. R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020874 · Cited by 52
“Studies have also shown that MLV tends to integrate near transcription start sites (within 5 kb upstream or downstream) of actively transcribed genes [26].”
BackgroundHost Factors in Retroviral Integration and the Selection of Integration Target Sites
Craigie, R., & Bushman, F. D. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0026-2014 · Cited by 45
“Subsequent studies have shown that this pattern is maintained in most cell lines studied (73, 74, 75, 76, 77, 78, 79, 80), with the exception of a few experimentally manipulated examples described below (Fig.”
BackgroundGonzález‐Murillo, Á., Lozano, M. L., Alvarez, L. A., Jacome, A., Almarza, E., Navarro, S., Segovia, J. C., Hanenberg, H., Güenechea, G., Bueren, J. A., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.141 · Cited by 59
“In addition, because of the safer integration pattern of LVs compared with RVs (Schroder et al., 2002; Wu et al., 2003; Mitchell et al., 2004; De Palma et al., 2005; Montini et al., 2006, 2009; GonzálezMurillo et al., 2008), we focused on LVs as therapeutic vectors to correct the phenotype of FA cells.”
Lentiviral vector integration sites in human NOD/SCID repopulating cells
Laufs, S., Güenechea, G., González‐Murillo, Á., Nagy, K. Z., Lozano, M. L., del Val, C., Jonnakuty, S., Hotz‐Wagenblatt, A., Zeller, W. J., Bueren, J. A., et al. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.958 · Cited by 55
“Recent data has shown the different integration pattern of MLV and HIV vectors within transcribed genes [39].”
InfluentialThe integration profile of EIAV-based vectors
Hacker, C. V., Vink, C. A., Wardell, T. W., Lee, S., Treasure, P., Kingsman, S. M., Mitrophanous, K. A., & Miskin, J. E. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.06.006 · Cited by 47
Integration Site Choice of a Feline Immunodeficiency Virus Vector
Kang, Y., Moressi, C. J., Scheetz, T. E., Xie, L., Tran, D. T., Casavant, T. L., Ak, P., Benham, C. J., Davidson, B. L., & McCray, P. B. (2006) · Journal of Virology · doi:10.1128/jvi.00719-06 · Cited by 46
“Overall, FIV integration preferences were similar to those reported for HIV (19) and SIV (6) and distinct from those reported for MLV, ASLV (17, 26), and FV (23).”
BackgroundMethodInfluentialGene therapy for severe combined immunodeficiencies
Gaspar, H. B., & Thrasher, A. J. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.9.1175 · Cited by 56
“From more recent studies it is clear that retroviruses show preference for integration into transcriptionally active genes and gammaretroviruses (as used in the SCID-X1 and ADA-SCID trials) in particular integrate preferentially into a 5-kb region around the transcription start site [45,46].”
BackgroundLentivirus-Mediated RNA Interference Therapy for Human Immunodeficiency Virus Type 1 Infection
Morris, K. V., & Rossi, J. J. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.479 · Cited by 52
“Lentiviruses, unlike retro-viruses such as Moloney murine leukemia virus (MoMLV), tend not to integrate in close proximity to active promoters but often within introns of an active transcriptional unit, potentially limiting their overall oncogenicity (Wu et al ., 2003).”
Gene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation
Levings, R. W., Palmer, G. D., Levings, P. P., Dacanay, E. A., Evans, C. H., & Ghivizzani, S. C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.901317 · Cited by 52
“γ-retroviral vectors preferentially integrate near the transcription start sites of active genes, with a particular affinity for proto-oncogenes (Wu et al., 2003), which brings the potential for insertional mutagenesis and oncogenic activation of the infected cell (Mitchell et al.”
BackgroundDooriss, K. L., Denning, G., Gangadharan, B., Javazon, E. H., McCarty, D., Spencer, H. T., & Doering, C. B. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.150 · Cited by 52
“An increasing body of evidence suggests that lentiviruses are inherently safer than g -oncoretroviruses, possibly because of differences in integration site preference (Schroder et al. , 2002; Wu et al. , 2003).”
Retroviral Vectors: Post Entry Events and Genomic Alterations
Nowrouzi, A., Glimm, H., Kalle, C. V., & Schmidt, M. (2011) · Viruses · doi:10.3390/v3050429 · Cited by 51
“HIV + − − [19,20] SIV + − − [67] MLV ± + + [18,19,67] ALV ± − − [17] ASLV ± − − [18] PFV − ± ± [14,15] EIAV + − ± [16,68] HTLV-1 ± − − [84,85]”
BackgroundMethodAo, Z., Jayappa, K. D., Wang, B., Zheng, Y., Wang, X., Peng, J., & Yao, X. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.317057 · Cited by 48
“The lentiviruses favor insertion of their genomes into active transcription units of the host chromosome (6, 7), whereas inmurine leukemia virus the viral integration favors chromatin loci near transcription start sites and CpG islands.”
BackgroundZeng, M., Alshehri, F., Zhou, D., Lara‐Sáez, I., Wang, X., Li, X., Sigen, A., Xu, Q., Zhang, J., & Wang, W. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b13135 · Cited by 49
Efficient transgenic rat production by a lentiviral vector
Michalkiewicz, M., Michalkiewicz, T., Geurts, A. M., Roman, R. J., Slocum, G. R., Singer, O., Weihrauch, D., Greene, A. S., Kaldunski, M., Verma, I. M., et al. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00060.2007 · Cited by 47
“This approach, which is a well-established method for cloning single-copy murine leukemia retrovirus or transposons inserts (3, 34), involves cloning and sequencing of each of the 3 and 5 -flanking regions surrounding each transgene insertion site.”
MethodSite‐Specific Integration with ϕC31 Integrase for Prolonged Expression of Therapeutic Genes
Ginsburg, D. S., & Calos, M. P. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)54008-2 · Cited by 48
Wolff, J. H., & Mikkelsen, J. G. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00865-4 · Cited by 47
The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy
Abou‐El‐Enein, M. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0272 · Cited by 48
QuickMap: a public tool for large-scale gene therapy vector insertion site mapping and analysis
Appelt, J.-U., Giordano, F. A., Ecker, M., Roeder, I., Grund, N., Hotz‐Wagenblatt, A., Opelz, G., Zeller, W. J., Allgayer, H., Früehauf, S., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.37 · Cited by 51
“A public available sequence set of 965 murine leukemia virus vector integrations in HeLa cells (Wu et al., 2003)(50) was used to generate an exemplary AnalyzerReport (available at http://www.”
MethodWells, D., Guo, S., Shao, W., Bale, M. J., Coffin, J. M., Hughes, S. H., & Wu, X. (2020) · BMC Genomics · doi:10.1186/s12864-020-6647-4 · Cited by 48
Self-citationA Hyperactive Transposase Promotes Persistent Gene Transfer of a piggyBac DNA Transposon
Burnight, E. R., Staber, J. M. R., Korsakov, P., Li, X., Brett, B. T., Scheetz, T. E., Craig, N. L., & McCray, P. B. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.12 · Cited by 50
“To determine if an integration occurred at a non-TTAA, for each integration site we evaluated the most frequently observed non-TTAA sequence and required that sequence (1) be present in greater than 50% of the reads and (2) match the reference genome.”
MethodKankkonen, H. M., Vähäkangas, E., Marr, R. A., Pakkanen, T. M., Laurema, A., Leppänen, P., Jalkanen, J., Verma, I. M., & Ylä‐Herttuala, S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.01.015 · Cited by 53
Gijsbers, R., Vets, S., De Rijck, J., Ocwieja, K. E., Ronen, K., Malani, N., Bushman, F. D., & Debyser, Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.255711 · Cited by 44
RetractedGene therapy strategies for hemophilia: benefits versus risks
Petrus, I., Chuah, M., & VandenDriessche, T. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1500 · Cited by 50
“By contrast, the potential oncogenic risk of lentiviral vectors may be reduced compared to γ -retroviral vectors because they integrate more distantly from transcriptional start sites, preferentially within highly expressed genes [108,110].”
BackgroundMethods for integration site distribution analyses in animal cell genomes
Ciuffi, A., Ronen, K., Brady, T., Malani, N., Wang, G., Berry, C. C., & Bushman, F. D. (2009) · Methods · doi:10.1016/j.ymeth.2008.10.028 · Cited by 45
Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly
Munter, S. D., Parys, A. V., Bral, L., Ingels, J., Goetgeluk, G., Bonte, S., Pille, M., Billiet, L., Weening, K., Verhee, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030883 · Cited by 46
“Next, while both lenti- and γ-retroviral vectors are used in clinical trials, there is a preference for lentiviral vectors due to their better safety profile [12,45,46].”
BackgroundHIV-based lentiviral vectors: Origin and sequence differences
Johnson, N. M., Alvarado, A. F., Moffatt, T. N., Edavettal, J. M., Swaminathan, T. A., & Braun, S. E. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.018 · Cited by 49
“Other studies revealed a preference for g-retroviral vector integration at TSS and CpG islands.(5,6) In a separate trial for WiskottAldrich syndrome (WAS) with a g-retroviral vector expressing WAS protein (WASP),(7) all nine patients with successful engraftment of WASP-positive hematopoietic stem cells (HSCs) for leas…”
BackgroundsiRNA delivery: from basics to therapeutic applications
Torchilin, V. (2013) · Frontiers in Bioscience · doi:10.2741/4087 · Cited by 46
“Diabetic retinopathy is the leading cause of newly diagnosed blindness in the working age (20-74) population in the United States and is the leading cause of vision loss in diabetic retinopathy.”
BackgroundArens, A., Appelt, J.-U., Bartholomae, C. C., Gabriel, R., Paruzynski, A., Gustafson, D., Cartier, N., Aubourg, P., Deichmann, A., Glimm, H., et al. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.219 · Cited by 45
“These efforts uncovered preferences of distinct gene transfer vectors to target gene coding regions, CpG islands, or transcriptional start sites (Schroder et al. , 2002; Wu et al. , 2003; Mitchell et al. , 2004).”
BackgroundGenotoxicity of retroviral hematopoietic stem cell gene therapy
Trobridge, G. D. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.562496 · Cited by 44
“Large-scale integration studies followed for the murine leukemia virus and avian sarcoma-leukosis virus gammaretroviruses [22-24], and for foamy retroviruses [25].”
BackgroundBlanco, E., Izotova, N., Booth, C., & Thrasher, A. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608653 · Cited by 48
“In conclusion, the leukemogenesis observed in some SCID-X1 patients treated with gene therapy predominantly originates from insertional mutagenesis associated with the gRVs, which (contrary to the previous belief) do not have a random integration pattern (92).”
BackgroundCadle-Davidson, M. M., & Owens, C. L. (2008) · Theoretical and Applied Genetics · doi:10.1007/s00122-008-0737-z · Cited by 45
“It is well documented that transposons, retroelements, and retroviruses insert into animal genomes in a nonrandom pattern, with 50 ends or transcriptional starts of expressed genes being preferred (Kidwell and Lisch 2001; Liao et al. 2000; Wu et al. 2003; Yant et al. 2005).”
BackgroundInsertional mutagenesis in zebrafish
Amsterdam, A. (2003) · Developmental Dynamics · doi:10.1002/dvdy.10381 · Cited by 49
“The apparent preference for insertions at the 5 end of the gene could be due to insertion preference, as has been suggested in mice (Scherdin et al., 1990; Mooslehner et al., 1990) and human tissue culture cells (Wu et al., 2003).”
BackgroundBimodal high-affinity association of Brd4 with murine leukemia virus integrase and mononucleosomes
Larue, R. C., Plumb, M. R., Crowe, B. L., Shkriabai, N., Sharma, A., DiFiore, J., Malani, N., Aiyer, S. S., Roth, M. J., Bushman, F. D., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku135 · Cited by 44
Novel Genome-Editing Tools to Model and Correct Primary Immunodeficiencies
de Bruin, L. M. O., Volpi, S., & Musunuru, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00250 · Cited by 45
“In vitro (28, 29) and in vivo studies (30–32) have demonstrated that lentiviral vectors integrate randomly in actively transcribed genes, without any preference for the transcription initiation sites and regulatory elements; thus, they are potentially safer (33).”
Harkey, M. A., Kaul, R., Jacobs, M. A., Kurre, P., Bovee, D., Levy, R., & Blau, C. A. (2007) · Stem Cells and Development · doi:10.1089/scd.2007.0015 · Cited by 42
“Multiarm analysis may also prove useful for examination of the integration site preferences of retroviral and other vector (15–17 , 25 ).”
Targeted gene insertion for molecular medicine
Voigt, K., Izsvák, Z., & Ivics, Z. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0381-8 · Cited by 45
“MLV has been shown to have a strong tendency to insert into transcription start sites of genes [2], whereas HIV exhibits a bias toward insertions into transcription units but without bias to transcription start sites [3].”
BackgroundChen, C., Li, X., Ge, G., Liu, J., Biju, K. C., Laing, S. D., Qian, Y., Ballard, C., He, Z., Masliah, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23795-4 · Cited by 44
Worsham, D. N., Schuesler, T., Kalle, C. V., & Pan, D. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.014 · Cited by 45
“Second, integration site mapping studies have revealed that murine leukemia virus (MLV) preferentially integrates in and around gene promoters (F1 kb from CpG islands), whereas HIV-1 integrates mostly within transcriptional units [31,32].”
Malik, P., Arumugam, P. I., Yee, J.-K., & Puthenveetil, G. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.030 · Cited by 48
Awakening gene therapy with Sleeping Beauty transposons
Essner, J. J., McIvor, R. S., & Hackett, P. B. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.015 · Cited by 44
Molecular mechanisms of HIV-1 proviral latency
Bisgrove, D., Lewinski, M., Bushman, F., & Verdin, E. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.5.805 · Cited by 43
Fetal and neonatal gene therapy: benefits and pitfalls
Waddington, S. N., Kennea, N. L., Buckley, S. M. K., Gregory, L. G., Themis, M., & Coutelle, C. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302375 · Cited by 44
Vanderbyl, S. L., MacDonald, G. N., Sidhu, S. S., Gung, L., Telenius, A., Perez, C. F., & Perkins, E. L. (2004) · Stem Cells · doi:10.1634/stemcells.22-3-324 · Cited by 44
Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease
Brommel, C. M., Cooney, A. L., & Sinn, P. L. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.138 · Cited by 45
“With good agreement, c-retroviral integration is enriched near enhancer and promoter regions of actively transcribed genes.(80,81) Lentiviral vectors are also enriched in transcribed genes but are predominantly found in introns.”
BackgroundInduced Pluripotent Stem Cells: Emerging Techniques for Nuclear Reprogramming
Han, J. W., & Yoon, Y. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3814 · Cited by 50
“Lentiviral vectors have a hypothetical safety advantage over retroviral vectors, because they lack the propensity to integrate near transcription start sites (201).”
BackgroundIntegration site selection by retroviruses.
Cereseto, A., & Giacca, M. (2004) · PubMed · Cited by 54
Progress Toward the Genetic Treatment of the β‐Thalassemias
Sadelain, M., Lisowski, L., Samakoglu, S., Rivella, S., May, C., & Rivière, I. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.010 · Cited by 44
Lever, A. M. L., Strappe, P., & Zhao, J. (2004) · Journal of Biomedical Science · doi:10.1007/bf02256092 · Cited by 58
Advances in Cell and Gene-based Therapies for Cystic Fibrosis Lung Disease
Oakland, M., Sinn, P. L., & McCray, P. B. (2012) · Molecular Therapy · doi:10.1038/mt.2012.32 · Cited by 51
Nuclear protein LEDGF/p75 recognizes supercoiled DNA by a novel DNA-binding domain
Tsutsui, K., Sano, K., Hosoya, O., Miyamoto, T., & Tsutsui, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr088 · Cited by 46
Factors that mold the nuclear landscape of HIV-1 integration
Bedwell, G. J., & Engelman, A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1207 · Cited by 44
“This analysis first revealed that while MLV integration preferred promoter regions, HIV-1 favored the interior regions of gene bodies (118).”
BackgroundDevelopment of a Synthetic Promoter for Macrophage Gene Therapy
He, W., Qiang, M., Ma, W., Valente, A. J., Quinones, M. P., Wang, W., Reddick, R. L., Xiao, Q., Ahuja, S. S., Clark, R. A., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.949 · Cited by 46
Biosafety Assessment of Site-directed Transgene Integration in Human Umbilical Cord–lining Cells
Sivalingam, J., Krishnan, S., Ng, W. H., Lee, S. S., Phan, T. T., & Kon, O. L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.61 · Cited by 42
Liu, H., Dow, E. C., Arora, R., Kimata, J. T., Bull–Otterson, L., Arduino, R. C., & Rice, A. P. (2006) · Journal of Virology · doi:10.1128/jvi.00542-06 · Cited by 47
“Integration by murine leukemia virus (MLV) occurs preferentially near transcriptional start sites, whereas that of human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus occurs preferentially anywhere within transcription units (9, 12, 14, 17, 20).”
BackgroundLarge-Scale Identification of Disease Genes Involved in Acute Myeloid Leukemia
Erkeland, S. J., Valkhof, M. G., Heijmans‐Antonissen, C., van Hoven-Beijen, A., Delwel, R., Hermans, M. H. A., & Touw, I. P. (2004) · Journal of Virology · doi:10.1128/jvi.78.4.1971-1980.2004 · Cited by 42
“We thank E. Rassart for providing the cell line that produced MuLV Gr-1.”
BackgroundInfluentialRecent advances in gene therapy for severe congenital immunodeficiency diseases
Sokolic, R. A., Kesserwan, C. A., & Candotti, F. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328302c807 · Cited by 42
Pigs taking wing with transposons and recombinases
Clark, K. J., Carlson, D. F., & Fahrenkrug, S. C. (2007) · Genome biology · doi:10.1186/gb-2007-8-s1-s13 · Cited by 46
“A further complication is the tendency of lentiviruses to insert into or near transcriptional units [114,115], increasing the likelihood of insertional mutagenesis or position effects from nearby endogenous enhancer elements.”
BackgroundZhang, W., Mück-Häusl, M., Wang, J., Sun, C., Gebbing, M., Miskey, C., Ivics, Z., Izsvák, Z., & Ehrhardt, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075344 · Cited by 41
DNA damage and gene therapy of xeroderma pigmentosum, a human DNA repair-deficient disease
Dupuy, A., & Sarasin, A. R. (2014) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2014.08.007 · Cited by 50
Experimental approaches for the generation of induced pluripotent stem cells
Sommer, C., & Mostoslavsky, G. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt26 · Cited by 46
“Lentiviral insertion sites are often found anywhere within the transcriptional unit, whereas gamma-retroviruses tend to integrate near transcriptional start sites [21].”
Background
Metadata
- Authors
- Wu, X., Li, Y., Crise, B., & Burgess, S. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Burgess, Shawn M.
- Venue
- Science
- Published
- 2003-06-13
- Volume
- 300
- Issue
- 5626
- Pages
- 1749-1751
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1637867377
- Cited by
- 1,305
- References
- 18
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 25 · 2020: 27 · 2019: 33 · 2018: 24 · 2017: 39 · 2016: 43 · 2015: 49 · 2014: 65 · 2013: 51 · 2012: 83
- FWCI
- 57.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01co12400-79-0-22)
- National Cancer Institute (N01CO12400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Chromosomal and Genetic Variations
- Keywords
- retroviral integration, transcription start sites, murine leukemia virus, HIV-1, human genome, gene therapy
- MeSH terms
- Child, Genetic Vectors, HeLa Cells, Humans, Leukemia, Leukemia Virus, Murine, Promoter Regions, Genetic, Transcription, Genetic, Tumor Cells, Cultured, Genetic Therapy, HIV-1, Gene Expression, Genome, Human, Virus Integration, CpG Islands, Oligonucleotide Array Sequence Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.